Venlafaxine Hydrochloride
Product Images NDC 68071-2588

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-2588). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2588 3)

This is a label of a medication product named Venlafaxine Hydrochloride 75mg, which comes in capsules. The label includes information about the manufacturer, lot number, and the expiration date of the medication. Additionally, there are warnings to keep the medication out of reach of children and store at controlled temperatures. However, there is not enough information available about the medical use and side effects of the medication.*

FDA Label Image

Figr1 (Figr1)

This is a drug interaction table that shows the interactions of several drugs with each other. The drugs mentioned are ethanol, Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, Imipramine, Lithium, and venlafaxine. The table provides information on the PK Fold Change and 90% Cl Recommendation for Cmax and AUC for these drugs. It also provides recommendations such as avoiding concomitant use, no dose adjustment, and use with caution in patients with hypertension, elderly or hepatic dysfunction.*

FDA Label Image

Figr2 (Figr2)

This appears to be a drug interaction table containing various drugs and their interaction with other drugs. It includes information such as the recommended dose adjustment, clinical significance, and the change relative to reference value. However, without knowing the context in which this table was obtained or the purpose it serves, it is difficult to provide a more detailed description.*

FDA Label Image

Figr3 (Figr3)

This is a summary of recommendations for dosing adjustments for the medication Venlafaxine in different special populations. The populations analyzed include individuals with hepatic impairment (cirrhosis, mild, moderate or mild/moderate), renal impairment (hemodialysis), CYP2D6 polymorphism, age (>60) and gender. The recommendations for each population are provided based on the analyte PK fold change and 90% CI. Dosage adjustments ranging from 25% to 50% or greater are recommended depending on the population and the analyte involved.*

FDA Label Image

Logo1 (Logo1)

FDA Label Image

Logo2 (Logo2)

FDA Label Image

Venlafaxinestructure (Venlafaxinestructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.